NRx Pharmaceuticals, Inc. today announced its financial results for the third quarter of 2022 and provided a business and clinical update.
Relief Therapeutics Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTD) (“Relief”), and NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) (“NRx Pharmaceuticals”), today announced that they have entered into definitive settlement agreements to resolve their pending litigation.
NRx Pharmaceuticals, Inc. is pleased to announce that on June 13, 2022, the plaintiffs in the securities class action lawsuit captioned “Dal Bosco v. NRx Pharmaceuticals, Inc. et al.” filed a notice in the U.S. District Court for the District of Delaware voluntarily dismissing the action against NRx Pharmaceuticals and its former officers. The dismissal was made without prejudice.
NRx Pharmaceuticals enrolled its first patient in one of two psychiatry studies being initiated this year; this first trial is studying patients with bipolar depression and sub-acute suicidality.
NRx Pharmaceuticals, Inc. today announced that management will report first quarter 2022 financial results prior to the market open on May 16, 2022.
NRx Pharmaceuticals, Inc. today announced that it has filed a new Breakthrough Therapy designation request with the U.S. Food and Drug Administration (FDA) focused on a subgroup of patients with Critical COVID-19 that in addition to aviptadil or placebo were also treated with remdesivir. The request includes safety data on approximately 750 patients treated with intravenous ZYESAMI® for Critical COVID-19.
NRx Pharmaceuticals, Inc. today announced its financial results for the year ended December 31, 2021 and provided a business update.
NRx Pharmaceuticals, Inc. announced that management will report year end 2021 financial results prior to the market open on March 31, 2022. The company will host a conference call and webcast on March 31, 2022, 8:30AM Eastern Time to discuss its results and provide a clinical and corporate update. Management will host the call, followed by a question-and-answer period.
NRx Pharmaceuticals, Inc. announced today that the company’s Board of Directors appointed Ira Strassberg as Chief Financial Officer and Treasurer effective March 15, 2022.